Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.

Thylén A, Hjerpe A, Martensson G.

Cancer. 2001 Sep 1;92(5):1224-30.

PMID:
11571736
2.

Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.

Thylén A, Levin-Jacobsen AM, Hjerpe A, Martensson G.

Eur Respir J. 1997 Feb;10(2):404-8.

3.

High CD44 expression on human mesotheliomas mediates association with hyaluronan.

Penno MB, Askin FB, Ma H, Carbone M, Vargas MP, Pass HI.

Cancer J Sci Am. 1995 Sep-Oct;1(3):196-203.

PMID:
9166476
4.

Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.

Hiraki A, Aoe K, Murakami T, Nakamura Y, Yamazaki K, Sueoka N, Taguchi K, Kamei T, Maeda T, Takeyama H, Kishimoto T, Nishimura M, Sugi K.

Oncol Rep. 2005 Aug;14(2):357-62.

PMID:
16012715
7.

Hyaluronan in pleural effusions and in serum.

Hillerdal G, Lindqvist U, Engström-Laurent A.

Cancer. 1991 May 1;67(9):2410-4.

PMID:
2013045
8.

Advances in the biology of malignant pleural mesothelioma.

Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, Santoro A.

Cancer Treat Rev. 2011 Nov;37(7):543-58. doi: 10.1016/j.ctrv.2011.01.001. Epub 2011 Feb 1. Review.

PMID:
21288646
9.

Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.

Kadota K, Villena-Vargas J, Nitadori J, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Ann Surg Oncol. 2015 Sep;22(9):3136-43. doi: 10.1245/s10434-015-4374-x. Epub 2015 Jan 22.

10.

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.

Thorax. 2014 Oct;69(10):895-902. doi: 10.1136/thoraxjnl-2014-205205. Epub 2014 Jul 18.

11.

Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.

Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E.

Lung Cancer. 2001 Nov;34(2):279-87.

PMID:
11679187
12.

Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.

Fusco V, Ardizzoni A, Merlo F, Cinquegrana A, Faravelli B, De Palma M, Chessa L, Nicolò G, Serra M, Capaccio A, et al.

Anticancer Res. 1993 May-Jun;13(3):683-9.

PMID:
8317897
13.
14.
15.

Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.

Battolla E, Canessa PA, Ferro P, Franceschini MC, Fontana V, Dessanti P, Pinelli V, Morabito A, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2017 Mar;37(3):1387-1391.

PMID:
28314308
16.

Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma.

Suzuki H, Hirashima T, Kobayashi M, Sasada S, Okamoto N, Uehara N, Tamiya M, Matsuura Y, Morishita N, Kawase I.

Anticancer Res. 2010 Oct;30(10):4343-6.

PMID:
21036761
17.

Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma.

Hanagiri T, Shinohara S, Takenaka M, Shigematsu Y, Yasuda M, Shimokawa H, Nagata Y, Nakagawa M, Uramoto H, So T, Tanaka F.

Tumour Biol. 2012 Dec;33(6):2135-41. doi: 10.1007/s13277-012-0473-5. Epub 2012 Aug 11.

PMID:
22886525
18.

Pleural fluid analysis in malignant mesothelioma. Prognostic implications.

Gottehrer A, Taryle DA, Reed CE, Sahn SA.

Chest. 1991 Oct;100(4):1003-6.

PMID:
1914546
19.

Prognostic factors and survival in malignant pleural mesothelioma.

Van Gelder T, Damhuis RA, Hoogsteden HC.

Eur Respir J. 1994 Jun;7(6):1035-8.

20.

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.

Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.

Lung Cancer. 2013 Dec;82(3):491-8. doi: 10.1016/j.lungcan.2013.09.016. Epub 2013 Oct 9.

PMID:
24161718

Supplemental Content

Support Center